Uliana Bell 10/3/24 Uliana Bell 10/3/24

Biopharmaceutical Research Company Announces First Dose of BRC-002, a First-in-Class Cannabinoid Therapeutic for Complex Regional Pain Syndrome (CRPS), in Investigator-Initiated Study

Biopharmaceutical Research Company Announces First Dose of BRC-002, a First-in-Class Cannabinoid Therapeutic for Complex Regional Pain Syndrome (CRPS), in Investigator-Initiated Study Read more →

Uliana Bell 9/12/24 Uliana Bell 9/12/24

First patient received BRC-001, a cannabinoid therapeutic, in a clinical trial investigating supportive care in breast cancer at City of Hope.

City of Hope and Biopharmaceutical Research Company announce first patient has received BRC-001 first-in-class cannabinoid therapeutic, in a clinical trial investigating supportive care in breast cancer Read more →

Uliana Bell 10/4/22 Uliana Bell 10/4/22

DEA-Licensed Cannabis Company Raises $20 Million

Monterey, CA – Biopharmaceutical Research Company (“BRC”), an active Drug Enforcement Administration (DEA) pharmaceutical cannabis license holder, announced the completion of a $20M Series A fundraise. This will enable the Company to aggressively scale its operations and increase its product offering, conduct sponsored research, and execute on its go-to-market strategy. Read more →

Uliana Bell 6/14/22 Uliana Bell 6/14/22

Open Book Extracts and BRC establish research and development collaboration

Roxboro, N.C. – Open Book Extracts (OBX), an NSF-certified manufacturer and distributor of the industry's most innovative and highest quality cannabinoid ingredients and finished products, today announces a collaboration with Biopharmaceutical Research Company (BRC). Read more →

Uliana Bell 11/13/21 Uliana Bell 11/13/21

BRC completes 1st import of commercial cannabis flower into the USA

The Colombian multinational shipped 30 kilograms of dried cannabis flower from its facilities in Portugal. The company continues to conquer the world in the midst of the 'boom' that the industry is going through. Read more →

Uliana Bell 11/9/21 Uliana Bell 11/9/21

BRC partners with Vanguard Scientific on technology integration for cannabis extraction

Biopharmaceutical Research Company partners with Vanguard Scientific on technology integration for cannabis extraction. Read more →

Uliana Bell 10/6/21 Uliana Bell 10/6/21

Clever Leaves exports its first commercial shipment of THC flower to the United States to BRC

Clever Leaves Holdings Inc. , a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, announced today the exportation of 30 kg of high-THC cannabis flower from its Portugal facility to Biopharmaceutical Research Company (“BRC”), a DEA-licensed pharmaceutical company that develops federally compliant active pharmaceutical ingredients (API) for plant-based therapeutics in the United States. Read more →

Uliana Bell 6/29/21 Uliana Bell 6/29/21

BRC and Segra complete 1st shipment of live cannabis plants into the USA

Segra International Corp, a leading cannabis agriculture technology company, is pleased to announce its first successful export of Verified Segra Stock™ Cannabis plantlets to the Biopharmaceutical Research Company (BRC), one of the first groups in the USA to receive approval from the DEA to cultivate Cannabis for scientific research purposes. Read more →

Uliana Bell 11/6/19 Uliana Bell 11/6/19

BRC and Washington State University to partner to study cannabis

Washington State University researchers and Biopharmaceutical Research Company (BRC) will partner to evaluate cannabis and accelerate the pace of cannabis research. The innovative partnership allows WSU scientists, many of whom are part of the university’s Collaborative for Cannabis Policy, Research and Outreach (CCPRO), greater access to cannabis for research purposes while remaining fully compliant with federal regulations governing cannabis. Read more →

Uliana Bell 9/19/19 Uliana Bell 9/19/19

BRC team praises former FDA commissioner’s call for increased cannabis research

Former Food and Drug Administration (FDA) Commissioner Scott Gottlieb has called for increased research into cannabis-derived treatments. Yesterday, the Senate Appropriations Committee issued a report in which it called on regulators to lower the regulatory burden on cannabis research. Read more →

Uliana Bell 8/26/19 Uliana Bell 8/26/19

BRC praises DOJ and DEA’s statement to move cannabis production for research forward

The DEA’s announcement that it will process applications to cultivate cannabis for research use is great news for scientists, health care providers, patients, and regulatory authorities. I started BRC with a dream of helping my fellow veterans use cannabis to treat their wartime wounds. Read more →

Uliana Bell 8/16/19 Uliana Bell 8/16/19

Addition of Lou Milione and Dr. Charles Schumacher to board of advisors

DEA Registrant Biopharmaceutical Research Company adds Celebrated Surgeon Charles Schumacher and Compliance Expert Louis Milione to Board of Advisors. Read more →